Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OTLK vs CBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OTLK Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–4 Matrix Metrics)

OTLK Overall Winner 6-Pillar Tally: OTLK 3 – 2 CBIO (1 Tie) Matrix Metrics: OTLK 5 – 4 CBIO

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CBIO carries 37.4/100 (SELL) at $13.05 (N/M Forward P/E, -1432.6% operating margin).

  • Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CBIO 37.4/100 SELL) and 1.47β · 79% Vol risk profile, whereas CBIO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CBIO is in a Breakdown options structure phase (RSI 47.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OTLK vs CBIO
OTLK NASDAQ Head-to-Head Winner
Outlook Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.40
-4.04% 1D
Market Cap $107.1M
TTM Revenue N/A
Forward P/E 2.9x
Beta / 30D Vol 1.47β · 79% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 71.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.48 · SMA50: $0.56
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.05
-7.77% 1D
Market Cap $533.8M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.41β · 62% Vol
Unified Composite Score
37.4 / 100 SELL
Tech 35.0 Fund 46.0 Flow 63.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.7 · SMA20: $13.50 · SMA50: $14.66

6-Pillar Scorecard Institutional Category Breakdown (OTLK 3 – 2 CBIO)

Columns: Metric · OTLK · CBIO
1. Valuation Multiples OTLK
Forward P/E 2.9x N/M
Trailing P/E 2.9x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 30.6x
2. Growth & Scale CBIO
Revenue Growth (YoY) -99.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $12M
Market Cap $107.1M $533.8M
3. Profitability & Quality OTLK
Gross Margin N/A 100.0%
Operating Margin 4781.8% -1432.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -3.6% -160.8%
4. Balance Sheet & Cash Flow CBIO
Cash Generation (TTM) -$56M -$154M
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.2M Net Debt $170M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OTLK
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 181.3% (55th %ile) 127.8% (10th %ile)
Put/Call OI Skew 0.26x (Call-Skewed) 1.07x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OTLK (5) vs CBIO (4)
Institutional Metric OTLK CBIO Criterion Row Edge
Market Capitalization
Scale
$107.1M $533.8M Larger Scale CBIO
Trailing P/E Ratio
Valuation
2.9x N/M Lower Multiple OTLK
Forward P/E Ratio
Valuation
2.9x N/M Lower Multiple OTLK
Revenue Growth (YoY)
Growth
-99.4% +0.0% Higher Growth CBIO
Operating Margin (TTM)
Profitability
4781.8% -1432.6% Higher Margin OTLK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-3.6% -160.8% Higher ROE OTLK
52-Week Range Position
Momentum
10% ($0–$3) 23% ($9–$27) Stronger Trend CBIO
Beta / 30D Volatility
Risk Regime
1.47β · 79% Vol 1.41β · 62% Vol Lower Realized Risk CBIO
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 37.4 / 100 (SELL) Higher Composite OTLK
Trailing 12M Revenue (USD)
Operating Scale
N/A $12M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 30.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$56M ($7.2M Net Debt) -$154M ($170M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CBIO +29.04 pp
OTLK: -18.82% · CBIO: +10.22%
3M Horizon CBIO +21.58 pp
OTLK: -43.39% · CBIO: -21.81%
6M Horizon OTLK +102.56 pp
OTLK: +72.91% · CBIO: -29.65%
1Y Horizon CBIO +73.58 pp
OTLK: -73.04% · CBIO: +0.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OTLK Revenue CBIO Revenue OTLK Op. Margin CBIO Op. Margin Margin Leader
FY2017 $0M N/A -941.4% N/A OTLK
FY2018 $0M N/A -960.1% N/A OTLK
FY2019 $10M N/A -445.6% N/A OTLK
FY2020 N/A $10M N/A -506.8% CBIO
FY2021 N/A $0M N/A -5470.7% CBIO
FY2022 N/A $0M N/A -63204.4% CBIO
FY2023 N/A $0M N/A -392752.9% CBIO
FY2025 $0M $10M -4744.3% -1407.5% CBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OTLK BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 181.3%
IV Percentile 55th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OTLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
144d in phase · OBV ACCUMULATION
Current IV 127.8%
IV Percentile 10th %ile
Put/Call OI Skew 1.07x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OTLK Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $533.8M market capitalization and -1432.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OTLK vs CBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CBIO carries 37.4/100 (SELL) at $13.05 (N/M Forward P/E, -1432.6% operating margin). Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CBIO 37.4/100 SELL) and 1.47β · 79% Vol risk profile, whereas CBIO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CBIO is in a Breakdown options structure phase (RSI 47.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CBIO leads the Growth & Scale pillar: OTLK posts -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin), compared with CBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (100.0% gross margin, -1432.6% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), OTLK cumulative revenue shifted N/A while CBIO shifted +0.0%. In operating R&D and SG&A reinvestment, OTLK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CBIO.

OTLK screens cheaper on headline valuation multiples. OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OTLK (-3.6% ROE) versus CBIO (-160.8% ROE) capital efficiency.

In options market volatility and institutional positioning, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk). By comparison, CBIO carries 127.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.